<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387305</url>
  </required_header>
  <id_info>
    <org_study_id>128206</org_study_id>
    <nct_id>NCT04387305</nct_id>
  </id_info>
  <brief_title>Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study</brief_title>
  <acronym>TIC-TOC</acronym>
  <official_title>Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Nishijima, MD, MAS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Emergency Care Applied Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trauma is the leading cause of death and disability in children in the United States. The&#xD;
      objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug&#xD;
      that stops bleeding) in severely injured children with hemorrhagic brain and/or torso&#xD;
      injuries. Using thromboelastography, we will measure baseline fibrinolysis to assess for&#xD;
      treatment effects of TXA at different levels of fibrinolysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TIC-TOC efficacy trial is a multicenter, adaptive allocation, randomized controlled trial&#xD;
      of children younger than 18 years with hemorrhagic injuries to the torso and/or brain to&#xD;
      evaluate the efficacy of TXA on functional outcome as measured by the PedsQL. Children will&#xD;
      be randomized to one of three arms: 1) TXA 15 mg/kg bolus over 30 minutes, followed by a 2&#xD;
      mg/kg/hr infusion over 8 hours), 2) TXA 30 mg/kg bolus over 30 minutes, followed by a 4&#xD;
      mg/kg/hr infusion over 8 hours), and 3) normal saline placebo. A third TXA dose (45 mg/kg&#xD;
      bolus dose over 30 minutes, followed by a 6 mg/kg/hr infusion over 8 hours) may be added&#xD;
      later in the trial if a dose effect based on accumulating data is noted. The trial will be&#xD;
      conducted in the Pediatric Emergency Care Applied Research Network (PECARN) across 40 sites&#xD;
      over 4 years of enrollment for a maximum sample size of 2000 patients.&#xD;
&#xD;
      A Bayesian adaptive randomization design will be used to evaluate the efficacy of TXA in&#xD;
      children with hemorrhagic brain and/or torso injuries. Because different types of injury have&#xD;
      different pathophysiology and potential response to TXA, three different injury strata will&#xD;
      be evaluated: isolated hemorrhagic brain injury, isolated hemorrhagic torso injury, and both&#xD;
      hemorrhagic brain and torso injuries. The efficacy of TXA will be analyzed across all&#xD;
      enrolled children as well as across each type of injury.&#xD;
&#xD;
      The Bayesian adaptive trial design also efficiently evaluates the effectiveness of TXA across&#xD;
      different TXA doses. The trial will randomize the first 500 patients to two doses of TXA and&#xD;
      placebo at a fixed 1:1:1 ratio. Interim analyses will be conducted when 500, 750, 1000, 1250,&#xD;
      1500, and 1750 patients have been enrolled. At each interim analysis, randomization&#xD;
      probabilities will be adjusted in order to preferentially allocate patients to better&#xD;
      performing doses, while allocation to the placebo arm will stay fixed. The adaptive&#xD;
      randomization will be based entirely on pre-planned rules using accumulating data. A Bayesian&#xD;
      hierarchical model will be used to estimate the treatment effect for each of the injury types&#xD;
      to be informed by the data accumulated from all injury types. At interim analyses, if a dose&#xD;
      effect is noted towards the higher dose of TXA (30 mg/kg bolus then a 4 mg/kg/hr infusion)&#xD;
      being more efficacious using pre-specified criteria, then a higher dose study arm (TXA 45&#xD;
      mg/kg bolus then a 6 mg/kg/hr infusion) will be opened later in the trial. If the dose&#xD;
      response curve is flat, suggesting that TXA is ineffective, then futility stopping rules can&#xD;
      end the trial early.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2022</start_date>
  <completion_date type="Anticipated">March 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bayesian adaptive response</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pediatric Quality of Life Inventory (PedsQL) area under the curve</measure>
    <time_frame>1 week, 1 month, 3 months, and 6 months (as measured as an area under the curve)</time_frame>
    <description>Neurocognitive functioning and quality-of-life measure; 0 to 100 with higher scores representing better outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracranial hemorrhage progression</measure>
    <time_frame>24 hours (Â±6 hours)</time_frame>
    <description>Intracranial hemorrhage progression on cranial computed tomography imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>First 48 hours after randomization</time_frame>
    <description>Total volume of packed red blood cells, platelets, fresh frozen plasma, and cryoprecipitate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL Physical Domain area under the curve</measure>
    <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
    <description>Physical domain of the PedsQL measure; 0 to 100 with higher scores representing better outcomes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Glasgow Outcome Scale-Extended (GOS-E) Peds</measure>
    <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
    <description>Global functioning as measured on an 8-point scale (8-death, 7-vegetative state, 6-lower severe disability, 5-upper severe disability, 4-lower moderate disability, 3-upper moderate disability, 2-lower good recovery, 1-upper good recovery)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale</measure>
    <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
    <description>Fatigue and cognitive function; 0 to 100 with higher scores representing better outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>D-dimer</measure>
    <time_frame>Change from baseline to end of 8-hour study drug infusion</time_frame>
    <description>Measure clot breakdown (ng/mL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasmin-antiplasmin (PAP) complex</measure>
    <time_frame>Change from baseline to end of 8-hour study drug infusion</time_frame>
    <description>Measure fibrinolytic activity (mcg/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Tissue plasminogen activator (tPA)</measure>
    <time_frame>Change from baseline to end of 8-hour study drug infusion</time_frame>
    <description>Measure fibrinolytic activity (ng/mL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Thrombosis</measure>
    <time_frame>1 week or at hospital discharge (whichever comes first)</time_frame>
    <description>Any venous or arterial thrombosis on standard diagnostic imaging post-randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Seizure</measure>
    <time_frame>1 week or at hospital discharge (whichever comes first)</time_frame>
    <description>Clinical or electroencephalogram-documented seizure</description>
  </other_outcome>
  <other_outcome>
    <measure>Behavior Rating Inventory of Executive Function (BRIEF)</measure>
    <time_frame>6 and 12 months after injury</time_frame>
    <description>Measurement of executive function after traumatic brain injury</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <condition>Wounds and Injury</condition>
  <condition>Hemorrhage</condition>
  <condition>Trauma Injury</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid 15 mg/kg bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 30 minutes followed by a 2 mg/kg/h infusion over 8 hours. This represents 31 mg/kg total dose of TXA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid 30 mg/kg bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 30 minutes followed by a 4 mg/kg/h infusion over 8 hours. This represents 62 mg/kg total dose of TXA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid 45 mg/kg bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 45 mg/kg bolus of tranexamic acid over 30 minutes followed by a 6 mg/kg/h infusion over 8 hours. This represents 91 mg/kg total dose of TXA. This dosing arm will only open if a dose-effect is determined based on accumulating data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tranexamic acid 15 mg/kg bolus</arm_group_label>
    <arm_group_label>Tranexamic acid 30 mg/kg bolus</arm_group_label>
    <arm_group_label>Tranexamic acid 45 mg/kg bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Less than 18 years old AND&#xD;
&#xD;
          2. Penetrating torso trauma, blunt torso trauma, or head trauma as defined below:&#xD;
&#xD;
          3. Penetrating Torso Trauma:&#xD;
&#xD;
             a. Penetrating trauma to the chest, abdomen, neck, or pelvis with at least one of the&#xD;
             following:&#xD;
&#xD;
               -  age-adjusted hypotension, or&#xD;
&#xD;
               -  age-adjusted tachycardia despite adequate resuscitation fluids, or&#xD;
&#xD;
               -  radiographic evidence of internal hemorrhage, or&#xD;
&#xD;
               -  clinician suspicion of ongoing internal hemorrhage&#xD;
&#xD;
          4. Blunt Torso Trauma:&#xD;
&#xD;
               1. Clinician suspicion of hemorrhagic blunt torso injury and at least one of the&#xD;
                  following:&#xD;
&#xD;
                    -  age-adjusted hypotension, or&#xD;
&#xD;
                    -  age-adjusted tachycardia despite adequate resuscitation fluids&#xD;
&#xD;
               2. Hemothorax on chest tube placement or imaging,&#xD;
&#xD;
               3. Clinical suspicion of hemorrhagic blunt torso injury and Intraperitoneal fluid on&#xD;
                  abdominal ultrasonography (Focused Assessment with Sonography in Trauma),&#xD;
&#xD;
               4. Intra-abdominal injury on CT with either contrast extravasation or more than&#xD;
                  trace intraperitoneal fluid,&#xD;
&#xD;
               5. Pelvic fracture with contrast extravasation or hematoma on abdominal/pelvic CT&#xD;
                  scan with at least one of the following:&#xD;
&#xD;
                    -  Age-adjusted hypotension, or&#xD;
&#xD;
                    -  Age-adjusted tachycardia.&#xD;
&#xD;
          5. Head Trauma:&#xD;
&#xD;
               1. Initial Glasgow Coma Scale (GCS) score 3 to 13 with associated intracranial&#xD;
                  hemorrhage on cranial CT scan (enroll after cranial CT scan)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to administer study drug within 3 hours of traumatic event&#xD;
&#xD;
          -  Known pregnancy&#xD;
&#xD;
          -  Known ward of the state&#xD;
&#xD;
          -  Cardiac arrest prior to randomization&#xD;
&#xD;
          -  GCS score of 3 with bilateral unresponsive pupils&#xD;
&#xD;
          -  Isolated subarachnoid hemorrhage, epidural hematoma, or diffuse axonal injury&#xD;
&#xD;
          -  Known venous or arterial thrombosis&#xD;
&#xD;
          -  Known bleeding/clotting disorders&#xD;
&#xD;
          -  Known seizure disorders&#xD;
&#xD;
          -  Known history of severe renal impairment&#xD;
&#xD;
          -  Known allergy to TXA&#xD;
&#xD;
          -  Unknown time of injury (includes suspected non-accidental trauma)&#xD;
&#xD;
          -  Previous enrollment into the TIC-TOC trial&#xD;
&#xD;
          -  Prior TXA for current injury&#xD;
&#xD;
          -  Prior opt-out&#xD;
&#xD;
          -  Non-English and non-Spanish speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel K Nishijima, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathan Kuppermann, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel K Nishijima, MD, MAS</last_name>
    <phone>916.734.3884</phone>
    <email>dnishijima@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathan Kuppermann, MD, MPH</last_name>
    <phone>916.734.1535</phone>
    <email>nkuppermann@ucdavis.edu</email>
  </overall_contact_backup>
  <link>
    <url>https://tictoctrial.org/</url>
    <description>TIC-TOC trial website</description>
  </link>
  <results_reference>
    <citation>Nishijima DK, Gosdin M, Naz H, Tancredi DJ, Hewes HA, Myers SR, Stanley RM, Adelson PD, Burd RS, Finkelstein Y, VanBuren J, Casper TC, Kuppermann N; TIC-TOC Collaborators of the Pediatric Emergency Care Applied Research Network (PECARN). Assessment of primary outcome measures for a clinical trial of pediatric hemorrhagic injuries. Am J Emerg Med. 2021 May;43:210-216. doi: 10.1016/j.ajem.2020.03.001. Epub 2020 Mar 9.</citation>
    <PMID>32278572</PMID>
  </results_reference>
  <results_reference>
    <citation>Trappey AF 3rd, Thompson KM, Kuppermann N, Stephenson JT, Nuno MA, Hewes HA, Meyers SR, Stanley RM, Galante JM, Nishijima DK; Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC) Collaborators of the Pediatric Emergency Care Applied Research Network (PECARN). Development of transfusion guidelines for injured children using a Modified Delphi Consensus Process. J Trauma Acute Care Surg. 2019 Oct;87(4):935-943. doi: 10.1097/TA.0000000000002432.</citation>
    <PMID>31299040</PMID>
  </results_reference>
  <results_reference>
    <citation>Powers PE, Shore KK, Perez S, Ritley D, Kuppermann N, Holmes JF, Tzimenatos LS, Shawargga H, Nishijima DK. Public Deliberation as a Novel Method for an Exception From Informed Consent Community Consultation. Acad Emerg Med. 2019 Oct;26(10):1158-1168. doi: 10.1111/acem.13827. Epub 2019 Jul 24.</citation>
    <PMID>31271691</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Daniel Nishijima, MD, MAS</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>Brain Injuries</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Children</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A public use database will be produced and will be completely de-identiï¬ed in accordance with the deï¬nitions provided in the Health Insurance Portability and Accountability Act (HIPAA).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>12 months after publication of primary manuscript.</ipd_time_frame>
    <ipd_access_criteria>Approval through NIH and PECARN</ipd_access_criteria>
    <ipd_url>https://www.pecarn.org/studyDatasets/Default</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

